The aim of our study was to evaluate the effectiveness of ethosuximide in the treatment of epileptic negative myoclonus, a motor disorder that can occur in childhood partial epilepsy. We introduced ethosuximide in nine patients with partial epilepsy of varying etiology (idiopathic, cryptogenic, symptomatic) who presented with epileptic negative myoclonus. The drug was added to the patients' preexisting antiepileptic drugs, which were maintained unchanged for the following 6 months. Epileptic negative myoclonus disappeared in all patients 15 to 30 days after ethosuximide was started. Plasma ethosuximide levels ranged from 55 to 89 μg/mL. The clinical response was not influenced by the patients' preexisting treatment or by the etiology of the epilepsy. No side effects were observed, and none of the patients presented a recurrence of epileptic negative myoclonus during follow-up. Furthermore, in five patients we observed the disappearance of partial seizures; in the remaining patients seizures were reduced by more than 75%. Electroencephalograms showed a decrement or disappearance of focal paroxysmal abnormalities. Our results suggest that ethosuximide is effective in the treatment of epileptic negative myoclonus and that it should be considered as a first-choice drug in the treatment of this motor disorder. (J Child Neurol 1999;14:395-400).
Get full access to this article
View all access options for this article.
References
1.
Tassinari CA , Regis H., Gastaut H.: A particular form of muscular inhibition in epilepsy: The related epileptic silent period (RESP) . Proc Aust Assoc Neurol1968;5:595-602.
2.
Tassinari CA : New perspectives in epileptology, in Japanese Epilepsy Association (ed): Trends in Modern Epileptology . Tokyo, Proceedings of the International Public Seminar on Epileptology , 1981, pp 42-59.
3.
Tassinari CA , Rubboli G., Parmeggiani L., et al: Epileptic negative myoclonus, in Fahn S, Hallett M, Luders HO, Marsden CD (eds): Negative Motor Phenomena. Advances in Neurology, vol. 67. Philadelphia , Lippincott-Raven, 1995, pp 181-197.
4.
Guerrini R., Dravet C., Genton P., et al: Epileptic negative myoclonus. Neurology1993;43:1078-1083.
5.
Cirignotta F. , Lugaresi E.: Partial motor epilepsy with "negative myoclonus."Epilepsia1991;32:54-58.
6.
Oguni H., Sato F., Hayashi K., et al: A study of unilateral brief focal atonia in childhood partial epilepsy. Epilepsia1992;33:75-83.
7.
Oguni H., Uehara T., Imai K., Osawa M.: Atonic epileptic drop attacks associated with generalized spike-and-slow-wave complexes: Video-polygraphic study in two patients. Epilepsia1997;38: 813-818.
8.
Rubboli G. Parmeggiani L, Tassinari CA: Frontal inhibitory spike component associated with epileptic negative myoclonus. Electroencephalogr Clin Neurophysiol1995;95:201-205.
9.
Oguni H., Uehara T., Tanaka T., et al: Dramatic effect of ethosuximide on epileptic negative myoclonus: Implications for the neurophysiological mechanism. Neuropediatrics1998;29:29-34.
Bodensteiner JB, Morris HH, Golden GS: Asterixis associated with sodium valproate . Neurology1981;31:194-195.
12.
Shields WD, Saslow E.: Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology1983;33:1487-1489.
13.
Ambrosetto G., Riva R., Baruzzi A.: Hyperammonemia in asterixis induced by carbamazepine: Two case reports. Acta Neurol Scand1984;69:186-189.
14.
Guerrini R. , Belmonte A., Strumia S., Hirsch E.: Exacerbation of epileptic negative myoclonus by carbamazepine or phenobarbital in children with atypical benign rolandic epilepsy, abstract. Epilepsia1995;36(Suppl 3):65.
15.
Obeso JA: Therapy of myoclonus. Clin Neurosci1996;3:253-257.
16.
Dalla Bernardina B., Fontana E., Michelizza B., et al: Partial epilepsies of childhood, bilateral synchronization, continuous spike wave during slow sleep, in Manelis J, Bental E, Loeber JN, Dreifuss FE (eds): Advances in Epileptology. XVIIth Epilepsy International Symposium. New York, Raven Press , 1989, pp 295-302.
17.
Gambardella A., Aguglia U., Oliveri RL, et al: Negative myoclonic status due to antiepileptic drug tapering: Report of three cases. Epilepsia1997;38:819-823.
18.
Baumgartner C., Podreka I., Olbrich A., et al: Epileptic negative myoclonus: An EEG-single-photon emission CT study indicating involvement of premotor cortex. Neurology1996;46:753-758.
19.
Noachtar S. , Holthausen H., Luders HO: Epileptic negative myoclonus. Subdural EEG recordings indicate a postcentral generator. Neurology1997;49:1534-1537.
20.
Aihara M., Hatakeyama K., Koizumi K., Nakazawa S.: Ictal EEG and single photon emission computed tomography in a patient with cortical dysplasia presenting with atonic seizures. Epilepsia1997;38:723-727.
21.
Degos JD, Verroust J., Bouchareine A., et al: Asterixis in focal brain lesions. Arch Neurol1979;36:705-707.
22.
Rio J., Montalban J., Pujadas F., et al: Asterixis associated with anatomic cerebral lesions: A study of 45 cases. Acta Neurol Scand1995;91:377-381.
23.
Tatu L., Moulin T., Martin V., et al: Astérixis unilatéral et lésions cérébrales focales. Douze cas. Rev Neurol (Paris)1996;152:121-127.
24.
Ferrendelli JA, Holland KD: Ethosuximide. Mechanisms of action, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs. New York, Raven Press, 1995, pp 649-654.
25.
Bromfield EB: Ethosuximide and other succinimides, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia , Lippincott-Raven, 1997, pp 1503-1508.
26.
Coulter DA, Hugenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol1989 ;25:582-593.
27.
Pelligrini A., Dossi RC, Dal Pos F., et al: Ethosuximide alters intrathalamic and thalamocortical synchronizing mechanism: A possible explanation of its antiabsence effect. Brain Res1989;497: 344-360.
28.
Mutani R., Cantello R., Gianelli M., Civardi C.: Antiepileptic drugs and mechanism of epileptogenesis. A review. Ital J Neurol Sci1995; 16:217-222.
29.
Steriade M. , Oakson G., Diallo A.: Cortically elicited spike-wave after discharges in thalamic neurons. Electroencephalogr Clin Neurophysiol1976;41:641-644.
30.
Avanzini G. , Vergnes M., Spreafico R., Marescaux C.: Calcium-dependent regulation of genetically determined spike and waves by the reticular thalamic nucleus of rats. Epilepsia1993;34:1-7.
31.
Tsakiridou E., Bertollini L., de Curtis M., et al: Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy . J Neurosci1995;15:3110-3117.
32.
Coulter DA: Thalamocortical anatomy and physiology, in Engel J Jr, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincott-Raven , 1997, pp 341-351.
33.
Young RR, Shahani BT: Asterixis: One type of negative myoclonus, in Fahn S (ed): Myoclonus. Advances in Neurology, vol 43. New York, Raven Press, 1986, pp 137-156.
